The largest database of trusted experimental protocols

Insulin glulisine

Manufactured by Sanofi

Insulin glulisine is a rapid-acting insulin analog used for the treatment of diabetes mellitus. It is a lab-produced form of human insulin that has been modified to have a faster onset and shorter duration of action compared to regular human insulin.

Automatically generated - may contain errors

3 protocols using insulin glulisine

1

Insulin Sensitivity Test in Animals

Check if the same lab product or an alternative is used in the 5 most similar protocols
The test was carried out on half of the animals from each group the day before the planned necropsy—the amount of glucose in the blood after an overnight fast was determined in dynamics 20, 40, 60, and 120 min after insulin administration (Insulin glulisine, Sanofi, subcutaneously, 2 IU/kg).
+ Open protocol
+ Expand
2

Peptide Hormones in Metabolic Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Organism species of all peptide hormones used in the present study were human: proinsulin (AmideBio), insulin (Wako), glucagon (Peptide Institute), GLP1 (1–36) amide and GLP1 (7-36) amide (KareBay Biochem), somatostatin-28 and somatostatin-14 (KareBay Biochem), desacyl ghrelin and ghrelin (Peptide Institute), and pancreatic polypeptide (KareBay Biochem). insulin detemir (Novo Nordisk), insulin glulisine (Sanofi), and insulin degludec (Novo Nordisk), which are used clinically, were used as representative insulin analogs.
+ Open protocol
+ Expand
3

Diabetes Treatment Preferences Survey

Check if the same lab product or an alternative is used in the 5 most similar protocols
Individuals were included in the study if they were aged ≥ 18 years, had been diagnosed with type 1 or type 2 diabetes, were using new RAIA (URLi [Eli Lilly and Company] and fast-acting insulin aspart [Novo Nordisk]), and/or conventional RAIA (insulin lispro [Eli Lilly and Company], insulin aspart [Novo Nordisk], insulin glulisine [Sanofi], and biosimilar products), and were able to participate in a web-based survey. Individuals were excluded from the study if they had been diagnosed with gestational diabetes.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!